Good neighbors, good friends, good comrades, and good partners for 60 years, the two countries are now building a closer community with a shared future
Production capacity cooperation is the heart of Lancang-Mekong Cooperation (LMC) in pursuit of common regional prosperity and synergized development. Such goals were enshrined in the Joint Statement on Production Capacity Cooperation among Lancang- Mekong Countries in 2016. A new initiative called “Multi- Nation, Multi-Park,” based on the experience of the China- Malaysia “Two Countries, Twin Parks” model, was launched at the 3rd LMC Leaders’ Meeting in August 2020. The leaders involved in designing the plan hold high expectations for its power to promote investment, create jobs, build capacity, reduce poverty, and foster technical and innovation cooperation.
The third volume of Xi Jinping: The Governance of China has been well received by local readers after its Chinese and English editions were released last year in countries neighboring China such as Malaysia, Singapore, Thailand, and Indonesia. Recently, leaders and alumni of Surya University and Surya College of Education, both renowned Indonesian private higher education institutions, shared their personal reflections on the book authored by Chinese leader Xi Jinping. Here, we present some selections from their writings.
Two days ago, I announced that China would provide Cambodia with 1 million doses of COVID-19 vaccines,” wrote Cambodian Prime Minister Samdech Techo Hun Sen in a January 17 Facebook post. “To boost confidence in the vaccine, I declare that I will be the first to be vaccinated in Cambodia. I must be at the forefront of this campaign.”
The office building of Beijing Institute of Biological Products Co., Ltd. (BJIBP) under China National Biotec Group (CNBG) in Beijing’s southeastern outskirts was still brightly lit at 9:00 p.m. on December 25, 2020. Dong Jianchun, head of engineering support, his deputy Shi Wei, and technical team leader Zhang Yu were feverishly pouring over a design plan for the company’s second production facility for the inactivated COVID-19 vaccine. They were checking implementation details related to the project as construction work entered the final stage and testing of production equipment was about to commence.
On a hot morning in July 2020, Liang Hongyang, deputy director of the No. 6 Vaccine Office of the Beijing Institute of Biological Products (BJIBP) under China National Biotec Group (CNBG), a subsidiary of China National Pharmaceutical Group (Sinopharm), rushed into the lab working on the COVID-19 vaccine. When he left the BJIBP building, Liang saw tents were pitched and people were waiting in a long queue to get vaccinated. He overheard someone say, “I finally feel safe after getting vaccinated.”